Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Mauna Kea Technologies Capital/Financing Update 2016

Jul 6, 2016

1507_rns_2016-07-06_b69d40f1-4ee5-4bfb-a746-4ac60ff8805f.html

Capital/Financing Update

Open in viewer

Opens in your device viewer

Mauna Kea Technologies: Half-Yearly Report on the Liquidity Contract with Gilbert Dupont

PARIS, July 06,2016 /PRNewswire/ --

Pursuant to the liquidity contract entrusted to Gilbert Dupont, on 30 June 2016 the following assets appeared on the liquidity account:

  • Number of shares: 30,282
  • Cash balance of the liquidity account: €81,237.08

As a reminder, at the time of the last Half-Yearly report on 31 December 2015, the following resources were booked to the liquidity account:

  • Number of shares: 36,363
  • Cash balance of the liquidity account: €64,689.01

About Mauna Kea Technologies

Mauna Kea Technologies is a global medical device company focused on eliminating uncertainties related to the diagnosis and treatment of cancer thanks to real time in vivo microscopic visualization. The Company's flagship product, Cellvizio, has received clearance to sell a wide range of applications in more than 40 countries, including the United States, Europe, Japan, China, Canada, Brazil and Mexico. For more information on Mauna Kea Technologies, visit www.maunakeatech.com

Mauna Kea Technologies

Benoit Jacheet

CFO

[email protected]

United States 

Zack Kubow / Lee Roth

The Ruth Group

+1-646-536-7020 / 7012

[email protected] 

[email protected]

U.S. Media

Christopher Hippolyte

The Ruth Grou

+1-646-536-7023

[email protected]

France and Europe

NewCap - Investor Relations

Florent Alba

+33-(0)1-44-71-94-94

[email protected]

This is a disclosure announcement from PR Newswire.